Solara Active Pharma Sciences Limited share price
NSE: SOLARA · ISIN INE624Z01016
Key numbers
- Market cap
- ₹ 3,566 Cr
- Current price
- ₹ 739.15
- 52-week high / low
- ₹ 774 / 422
- Stock P/E
- -
- Book value
- ₹ 287.1
- Dividend yield
- 0.00%
- ROCE
- 3.6%
- ROE
- -0.6%
- Debt to equity
- 0.55
- Sales growth (3 yrs)
- -1.2%
- Profit growth (3 yrs)
- -
- 1-year return
- 14.9%
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. It offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immuno-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. The…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 319 | 314 | 349 | 387 | 382 |
| Operating profit | 57 | 35 | 37 | 58 | 62 |
| Net profit | 11 | -10 | -17 | 10 | 16 |
| EPS (₹) | 2.46 | -2.36 | -3.98 | 2.20 | 3.52 |
Concall summary (2026-07-29)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Gautami, again, we will be slightly shying away from giving an outlook, but 25% plus/minus 1% should be the margin profile what we're looking at in terms of EBITDA profile.
- And when it comes to sustainability in the future, we are fairly confident that we should be able to sustain these levels, we are fairly confident of growing this business by at least 10% year-on- year kind of number.
Growth & demand
- So when I look from our Q1 FY '26 to Q1 FY '27, growth in revenue is significantly higher in terms of 24%.
- Even if I adjust the whatever increased pass-through cost, that number will be still more than 18%, 19% of a growth, which we believe is a healthier as well as sustainable growth parameter.
Margins & costs
- Gross margins was at INR158 crores, up 10% year-on-year and EBITDA at INR72 crores, up 8% year-on-year.
- We reported an EBITDA margin of negative 12% amidst what we think is a difficult operating environment.
Capex & expansion
- Now when it comes to whatever capex expansion or say, usage of the operational cash flows, what we will be generating, we expect on an average close to INR40 crores to INR50-odd crores of capex year-on-year from FY '28 and FY '29 as well.
- FY '27, we have already committed to close to INR55 - INR60-odd crores of capex.
Balance sheet & cash
- Now the second pillar is in terms of profitability, driven by this gross margin profile of 52% plus as well as an operating cost leverage.
- So we have reduced our net debt by close to INR135-odd crores, which is 22% reduction in net debt in the last 6,7 months.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.